Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
PaperCitations, authors & open-access status
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 4,112 citations, 2011 year and closed oa status.
4,112
Citations
2011
Year
closed
OA Status